Skip header and navigation

Refine By

20 records – page 1 of 2.

Adenocarcinoma of the prostate in perspective.

https://arctichealth.org/en/permalink/ahliterature248080
Source
Can Med Assoc J. 1978 Nov 4;119(9):1077-84
Publication Type
Article
Date
Nov-4-1978
Author
A W Bruce
D E Mahan
Source
Can Med Assoc J. 1978 Nov 4;119(9):1077-84
Date
Nov-4-1978
Language
English
Publication Type
Article
Keywords
Acid Phosphatase - blood
Adenocarcinoma - therapy
Aged
Bone Neoplasms - diagnosis
Clinical Enzyme Tests
Ethinyl Estradiol - therapeutic use
Evaluation Studies as Topic
Humans
Immunologic Techniques
Lymph Nodes - pathology
Male
Middle Aged
Neoplasm Metastasis
Neoplasm Staging
Ontario
Prostate - pathology
Prostatic Neoplasms - pathology - therapy
Radiotherapy, High-Energy
Seminal Vesicles - pathology
Abstract
Adenocarcinoma of the prostate is responsible for one of every nine deaths from cancer in Canada. In this review epidemiologic factors are considered and current staging systems are outlined. The American Urological System is recommended for staging because of its ability to reflect changes in the understanding of the biologic behaviour of this neoplasm. The adoption of a quantitative grading scheme is suggested to complement the information obtained from the staging assessment. The routes of spread of this disease, along with the procedures used to assess metastatic involvement, are described. Immunologic methods for the analysis of prostatic acid phosphatase have been shown to be superior to the enzymatic methods previously used, and the role of the new techniques is discussed. Emphasis is placed on radiotherapy and endocrine therapy for the treatment of this neoplasm, and the concept of withholding endocrine therapy until symptoms appear is discussed. Potential future developments in this field are considered.
Notes
Cites: J Urol. 1976 Jan;115(1):86-81107604
Cites: Urol Clin North Am. 1975 Feb;2(1):105-241128746
Cites: Cancer Res. 1975 Sep;35(9):2446-521170944
Cites: J Urol. 1976 Apr;115(4):409-121263317
Cites: J Pathol Bacteriol. 1953 Jul;66(1):91-313109621
Cites: Cancer. 1954 Jul;7(4):690-70313172685
Cites: Calif Med. 1954 Nov;81(5):308-1313209358
Cites: Cancer Res. 1954 Nov;14(10):718-2413209548
Cites: J Am Med Assoc. 1956 Mar 10;160(10):838-913295029
Cites: Am J Med. 1956 Nov;21(5):697-71313362301
Cites: J Urol. 1959 Jan;81(1):194-613631798
Cites: Am J Med. 1959 Dec;27:902-1013845841
Cites: Ann Surg. 1940 Jul;112(1):138-4917857618
Cites: J Urol. 1977 Apr;117(4):459-63321808
Cites: Cancer. 1978 May;41(5):1788-93348296
Cites: J Urol. 1973 Aug;110(2):242-44124679
Cites: CA Cancer J Clin. 1974 Sep-Oct;24(5):282-84138838
Cites: J Urol. 1978 Jan;119(1):94-8413938
Cites: J Urol. 1967 Dec;98(6):686-924169732
Cites: J Urol. 1968 Jan;99(1):79-864170153
Cites: Invest Urol. 1968 Jan;5(4):371-84170388
Cites: J Urol. 1970 Apr;103(4):462-64191242
Cites: Br J Urol. 1973 Dec;45(6):668-774359746
Cites: Surg Clin North Am. 1974 Aug;54(4):887-954428321
Cites: Cancer. 1973 Nov;32(5):1126-304585929
Cites: S Afr Med J. 1973 Feb 3;47(5):179-804684246
Cites: Cancer. 1973 Nov;32(5):1092-54757906
Cites: J Urol. 1974 May;111(5):644-64823973
Cites: Cancer. 1972 Apr;29(4):941-55017363
Cites: J Urol. 1972 Dec;108(6):897-9005082743
Cites: Can Med Assoc J. 1971 Jul 10;105(1):71-25088479
Cites: Radiology. 1971 Feb;98(2):343-515099838
Cites: Br J Urol. 1971 Oct;43(5):520-25118130
Cites: N Y State J Med. 1966 Feb 1;66(3):351-55216613
Cites: Can Med Assoc J. 1970 Aug 15;103(4):372-35447717
Cites: Radiol Clin North Am. 1970 Aug;8(2):259-705453484
Cites: Radiology. 1971 Apr;99(1):192-65548678
Cites: J Natl Cancer Inst. 1968 Jan;40(1):43-685635018
Cites: Cancer. 1969 Jan;23(1):24-345763258
Cites: J Urol. 1965 Nov;94(5):604-65846201
Cites: J Urol. 1967 Jun;97(6):1075-76067543
Cites: Cancer. 1978 Apr;41(4):1433-9639003
Cites: Urology. 1978 May;11(5):542675916
Cites: Urology. 1978 Jun;11(6):599-602675926
Cites: Cancer Treat Rep. 1977 Mar-Apr;61(2):173-8068821
Cites: Cancer Treat Rep. 1977 Mar-Apr;61(2):193-20068822
Cites: Cancer Treat Rep. 1977 Mar-Apr;61(2):205-1068824
Cites: N Engl J Med. 1977 Dec 22;297(25):1357-6173133
Cites: Invest Urol. 1978 Jan;15(4):319-2375196
Cites: CA Cancer J Clin. 1975 Jan-Feb;25(1):2-8804962
Cites: Annu Rev Med. 1975;26:567-88807150
Cites: J Urol. 1977 Feb;117(2):197-8833967
Cites: Arch Androl. 1978 May;1(3):227-3383815
Cites: Arch Androl. 1978 May;1(3):235-983816
Cites: J Urol. 1977 Mar;117(3):319-22839593
Cites: Urology. 1977 Mar;9(3):273-5841802
Cites: Radiology. 1977 May;123(2):319-22847193
Cites: Cancer Treat Rep. 1977 Mar-Apr;61(2):223-5872130
Cites: J Urol. 1977 Nov;118(5):733-8916091
Cites: Urology. 1976 Jun;7(6):598-601936380
Cites: Urology. 1976 Jun;7(6):602-10936381
Cites: J Urol. 1976 Aug;116(2):206-10950705
Cites: J Urol. 1976 Aug;116(2):211-3950706
Cites: Cancer. 1976 Nov;38(5):2078-87991119
PubMed ID
105800 View in PubMed
Less detail

[Considerations on the enzyme diagnosis of pulmonary cancer].

https://arctichealth.org/en/permalink/ahliterature110080
Source
Med Lab (Stuttg). 1969 May;22(5):118-21
Publication Type
Article
Date
May-1969
Author
L. Perret
Source
Med Lab (Stuttg). 1969 May;22(5):118-21
Date
May-1969
Language
French
Publication Type
Article
Keywords
Clinical Enzyme Tests
Finland
Humans
L-Lactate Dehydrogenase - blood
Lung Neoplasms - enzymology - epidemiology
PubMed ID
5802984 View in PubMed
Less detail

Convictions for drunkenness or drunken driving, sick absenteeism, and morbidity in middle-aged males with different levels of serum gamma-glutamyltransferase.

https://arctichealth.org/en/permalink/ahliterature243097
Source
Prev Med. 1982 Jul;11(4):403-16
Publication Type
Article
Date
Jul-1982

A cost effectiveness analysis of thiopurine methyltransferase testing for guiding 6-mercaptopurine dosing in children with acute lymphoblastic leukemia.

https://arctichealth.org/en/permalink/ahliterature136779
Source
Pediatr Blood Cancer. 2011 Aug;57(2):231-9
Publication Type
Article
Date
Aug-2011
Author
Jennifer R Donnan
Wendy J Ungar
Maria Mathews
Rebecca L Hancock-Howard
Proton Rahman
Author Affiliation
Department of Health Policy, Management & Evaluation, University of Toronto, Toronto, Ontario, Canada.
Source
Pediatr Blood Cancer. 2011 Aug;57(2):231-9
Date
Aug-2011
Language
English
Publication Type
Article
Keywords
6-Mercaptopurine - administration & dosage - adverse effects
Antimetabolites, Antineoplastic - administration & dosage - adverse effects
Bone Marrow Diseases - chemically induced - prevention & control
Child, Preschool
Clinical Enzyme Tests - economics
Cost-Benefit Analysis
Decision Trees
Drug Dosage Calculations
Genetic Testing - economics
Genotype
Humans
Methyltransferases - deficiency - genetics
Models, Econometric
Ontario
Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy - enzymology - genetics
Sensitivity and specificity
Survival Analysis
Abstract
An increased understanding of the genetic basis of disease creates a demand for personalized medicine and more genetic testing for diagnosis and treatment. The objective was to assess the incremental cost-effectiveness per life-month gained of thiopurine methyltransferase (TPMT) genotyping to guide doses of 6-mercaptopurine (6-MP) in children with acute lymphoblastic leukemia (ALL) compared to enzymatic testing and standard weight-based dosing.
A cost-effectiveness analysis was conducted from a health care system perspective comparing costs and consequences over 3 months. Decision analysis was used to evaluate the impact of TPMT tests on preventing myelosuppression and improving survival in ALL patients receiving 6-MP. Direct medical costs included laboratory tests, medications, physician services, pharmacy and inpatient care. Probabilities were derived from published evidence. Survival was measured in life-months. The robustness of the results to variable uncertainty was tested in one-way sensitivity analyses. Probabilistic sensitivity analysis examined the impact of parameter uncertainty and generated confidence intervals around point estimates.
Neither of the testing interventions showed a benefit in survival compared to weight-based dosing. Both test strategies were more costly compared to weight-based dosing. Incremental costs per child (95% confidence interval) were $277 ($112, $442) and $298 ($392, $421) for the genotyping and phenotyping strategies, respectively, compared to weight-based dosing.
The present analysis suggests that screening for TPMT mutations using either genotype or enzymatic laboratory tests prior to the administration of 6-MP in pediatric ALL patients is not cost-effective.
Notes
Comment In: Pediatr Blood Cancer. 2011 Dec 15;57(7):124721796762
PubMed ID
21344614 View in PubMed
Less detail

Effect of prednisone on the survival of patients with cirrhosis of the liver. A report from the Copenhagen Study Group for Liver Diseases.

https://arctichealth.org/en/permalink/ahliterature110256
Source
Lancet. 1969 Jan 18;1(7586):119-21
Publication Type
Article
Date
Jan-18-1969

Enzymuria in workers exposed to inorganic mercury.

https://arctichealth.org/en/permalink/ahliterature233884
Source
Int Arch Occup Environ Health. 1988;61(1-2):65-9
Publication Type
Article
Date
1988
Author
L. Barregård
B. Hultberg
A. Schütz
G. Sällsten
Author Affiliation
Department of Occupational Medicine, Sahlgren Hospital, University of Göteborg, Sweden.
Source
Int Arch Occup Environ Health. 1988;61(1-2):65-9
Date
1988
Language
English
Publication Type
Article
Keywords
Acetylglucosaminidase - urine
Albuminuria - chemically induced
Chemical Industry
Clinical Enzyme Tests
Cross-Sectional Studies
Hexosaminidases - urine
Humans
Kidney Diseases - chemically induced - diagnosis
Longitudinal Studies
Male
Mercury - adverse effects - analysis
Occupational Diseases - chemically induced - diagnosis
Sweden
Abstract
Urinary excretion of beta-hexosaminidase (NAG = N-acetyl-beta-glucosaminidase) and albumin was examined in 41 chlor-alkali workers exposed to inorganic mercury and 41 age-matched controls. Either U-HG or B-Hg levels for these workers were available dating from the 1960s to the present. Increased U-NAG was seen in workers with a U-Hg today of more than 4 micrograms/mmol creat (about 50 micrograms/l: 35 ug/g creat). Multiple linear regression analysis showed that U-NAG was correlated to U-Hg and integrated dose but not to the present B-Hg level. No albuminuria (detection limit 12.5 mg/l) was found in any of the subjects. In a longitudinal study, no decrease in U-NAG levels was seen in 15 chlor-alkali workers after their vacation (means = 20d). In five workers followed for ten months after a short exposure period, no definite time trend could be seen. The results show that there is a slight effect on renal tubules even at rather low levels of exposure to mercury vapour. The clinical significance of the enzymuria levels found here is, however, debatable.
PubMed ID
3264272 View in PubMed
Less detail

20 records – page 1 of 2.